Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

China flag China · Delayed Price · Currency is CNY
15.71
+0.01 (0.06%)
Mar 10, 2026, 11:44 AM CST
94.67%
Market Cap 8.46B
Revenue (ttm) 970.32M
Net Income (ttm) -272.78M
Shares Out 538.65M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,334,000
Average Volume 17,406,072
Open 15.26
Previous Close 15.70
Day's Range 15.26 - 16.10
52-Week Range 6.64 - 22.63
Beta 0.60
RSI 49.26
Earnings Date Apr 28, 2026

About SHE:300497

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,774
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300497
Full Company Profile

Financial Performance

In 2024, SHE:300497's revenue was 1.18 billion, a decrease of -26.83% compared to the previous year's 1.61 billion. Losses were -272.10 million, 35.5% more than in 2023.

Financial Statements

News

There is no news available yet.